A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer

Abstract

. Nevertheless, many patients still failed to treatment due to tumor recurrence and metastasis, and 5-year survival rate still less than 10%.Pemetrexed is a new anticancer drug. 2 by 10 minute infusion on day 1, repeated every 3 weeks. Doses were modified depending on nadir counts of blood cells. Combined chemotherapeutic agents included irinotecan, lobaplatin, carboplatin, oxaliplatin, gemcitabine, cis-platinum or bevacizumab. Multiple variables (age, sex, hemoglobin, platinum drugs combined, metastasis sites, LDH, ALP, CEA>40 ug/ml) reported earlier were selected.We used logistic regression analysis to evaluate relationships between these and tumor response. Results: On multivariable analysis, we found that age was significant in predicting the responsiveness to pemetrexed (p<0.05) combined with oxaliplatin. We did not find any other factors which were significantly associated with the response rate to chemotherapy with pemetrexed and irinotecan. Conclusions: By multivariate analysis, we found that age had significant impact on the responsiveness of pemetrexed when combined with oxaliplatin. Additional research based on genomic properties of host and tumors are needed to clarify markers for better selection of patients who could benefit from pemetrexed combined chemotherapy.

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

“…Its use, however, is limited by sometimes severe organ toxicity, especially neuro-and nephrotoxicity. Carboplatin shows a favorable spectrum of toxicity, with reversible myelosuppression being the dose-limiting toxicity (Deng et al, 2013;Huang et al, 2013;Peng et al, 2014;Wang et al, 2014;Wu et al, 2014;Zhao et al, 2014). Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin.…”

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

“…Analysis was performed using Statistica version 8.0 software (StatSoft Inc., Tulsa, OK) with p<0.05 described as statistically significant. We have enough experience in conducting medical researches, and have published some results elsewhere (Qian et al, 2014;Ji et al, 2014;Huang et al, 2014;Wu et al, 2014;Xiao et al, 2014;Lu et al, 2014;Xu et al, 2014;Gong et al, 2014;Wu et al, 2013;. …”

A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia

“…After TP and PTP were attempted, safety and effectiveness were evaluated. We have enough experience in conducting medical researches, and have published some cancer related results elsewhere Cao et al, 2014;Cui et al, 2014;Ji et al, 2014;Lu et al, 2014;Qian et al, Tian et al, 2014;Wu et al, 2014;Cui et al, 2015;Li et al, 2015;Qian et al, 2015;Shen et al, 2015;Shi et al, 2015;Sun et al, 2015;Wang et al, 2015;Yang et al, 2015;Zhou et al, 2015) …”